| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447458 | European Journal of Cancer | 2011 | 12 Pages |
Abstract
KRAS mutation status is a treatment effect modifier for anti-EGFR antibodies in metastatic CRC. Further evidence is needed to determine whether this is true for all chemotherapy partners and all clinical circumstances.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Barbara-Ann Adelstein, Timothy A. Dobbins, Carole A. Harris, Ian C. Marschner, Robyn L. Ward,